-- 
Bankinter, Bongrain, Nyrstar, Vopak: European Equity Preview

-- B y   C e c i l e   V a n n u c c i
-- 
2011-03-11T05:01:01Z

-- http://www.bloomberg.com/news/2011-03-10/bankinter-bongrain-nyrstar-nv-thrombogenics-nv-european-equity-preview.html
The following companies’ shares may
have unusual moves in European trading. Stock symbols are in
parentheses.  The Stoxx Europe 600 Index fell 1.2 percent to 277.88. The
Stoxx 50 Index declined 1 percent to 2,611.80. The Euro Stoxx 50
Index, a benchmark for nations using the euro, dropped 0.9
percent to 2,909.73.    Bankinter SA (BKT)  : The Spanish lender needs 333 million
euros of new capital, the Bank of  Spain  said. The bank has said
it will issue 406 million euros in bonds that must be converted
into shares. The stock lost 1.6 percent to 4.58 euros.    Bongrain SA (BH)  : The dairy-product manufacturer said
net income rose 83 percent in 2010 to 81.4 million euros last
year. The company will pay a dividend of 1.6 euros per share.
The shares of Bongrain rose 1.2 percent to 62.83 euros.  Nyrstar NV (NYR BB): Existing investors in the world’s
largest producer of refined zinc have until 4 p.m. in Brussels
to buy seven new shares at 7 euros apiece for every 10 they
hold.  Nyrstar (NYR)  lost 2.5 percent to 9.91 euros. The subscription
rights (NYR3 BB) fell 8.6 percent to 2.01 euros.  Royal Vopak NV (VPK NA): The world’s largest chemical and
oil storage company may report full-year net income rose to
276.8 million euros, according to the average estimate of nine
analysts surveyed by Bloomberg. Vopak retreated 0.9 percent to
34.78 euros.    Telegraaf Media Groep NV (TELEG)  : The Dutch newspaper
publisher may report full-year profit excluding some items of
52.9 million euros ($73.1 million), according to the average of
four analyst estimates compiled by Bloomberg. Telegraaf rose 0.1
percent to 14.32 euros.    ThromboGenics NV (THR)  : The Belgian developer of the
microplasmin retinal-disorder medicine said it plans to seek
U.S. and European regulatory approval for the experimental drug
in the second half of 2011. The company had 109.2 million euros
of cash and short-term investments on Dec. 31. The shares
dropped 0.8 percent to 20.69 euros.  To contact the reporter on this story:
Cecile Vannucci in New York at 
 cvannucci1@bloomberg.net   To contact the editor responsible for this story:
Nick Baker at 
 nbaker7@bloomberg.net  